Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Shionogi Boosts Stake in Tetra under Alzheimer's Deal; Buyout on the Cards
Shionogi said on March 6 that it has entered into new investment and merger agreements with its US partner Tetra Therapeutics to bolster their existing strategic partnership for the development of a phosphodiesterase-4D (PDE4D) inhibitor, by increasing its stake in…
To read the full story
Related Article
- Shionogi/Tetra’s Cognitive Disorder Med Delivers Positive PII Data
November 4, 2020
- Shionogi Snaps Up Tetra after PII Alzheimer’s Study Completed
May 27, 2020
- Shionogi Licenses Cognitive Disorders Treatment Candidate from Tetra
December 20, 2018
BUSINESS
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
February 4, 2026
- Fuji, Richter Expand Gynecology Partnership to Accelerate R&D
February 4, 2026
- Senju, Novartis Ink Promotion Tie-Up for Eye Drug Beovu in Japan
February 4, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…